Home About us ERCS Facilities Queries Contact
    Diabetic retinopathy >>Intravitreal Triamcinolone acetonide  
Medical & Para Medical Staff Members School Health Programme
 
  About Us
  Staff & Infrastructure
  Facilities
  ERCS_ _ _ _ _ _ _ _ _ _ _ _ _ _ _
  Introduction
  Activities
  Appeal
  Patient Information _ _ _ _ _ _ _
  Catract
  Glaucoma
  Diabetic Retinopathy
  Refractive Errors
  Training Programs_ _ _ _ _ _ _ _
  Fellowship Courses
  Course Descriptions
  Surgical Training Programs
  Related Links_ _ _ _ _ _ _ _ _ _ _
  Ophthalmic Journals And Websites
  Listservs And Discussion Groups
  Recognization
Diabetic retinopathy

Triamcinolone is a long acting steroid preparation. When injected in the vitreous cavity, it results in a decrease in the macular edema (thickening of the retina at the macula) caused due to diabetic maculopathy, along with an increase in the visual acuity. The effect of triamcinolone is transient, lasting up to three months, and necessitating repeated injections for maintaining the beneficial effect. Complications of intravitreal injection of triamcinolone include cataract, steroid induced glaucoma and endophthalmitis.

Instead of laser surgery, some people need an eye operation called a vitrectomy to restore vision. A vitrectomy is performed when there is a lot of blood in the vitreous. It involves removing the cloudy vitreous and replacing it with a saline solution. Studies show that people who have a vitrectomy soon after a large hemorrhage are more likely to protect their vision than someone who waits to have the operation.

Early vitrectomy is especially effective in people with insulin-dependent diabetes, who may be at greater risk of blindness from a hemorrhage into the eye. Vitrectomy is often done under local anesthesia. The doctor makes a tiny incision in the sclera, or white of the eye. Next, a small instrument is placed into the eye to remove the vitreous and insert the saline solution into the eye. Patients may be able to return home soon after the vitrectomy, or may be asked to stay in the hospital overnight.

After the operation, the eye will be red and sensitive, and patients usually need to wear an eyepatch for a few days or weeks to protect the eye. Medicated eye drops are also prescribed to protect against infection.
Though not yet commercially available, c-peptide has shown promising results in treatment of diabetic complications incidental to vascular degeneration. Once thought to be a useless byproduct of insulin production, it helps to ameliorate and reverse many symptoms of diabetes. Experimental Therapy Near-Infrared Light (NIR) Therapy for Diabetic Macular Edema: A Pilot Study This study is currently recruiting participants. Near-infrared light (NIR) via light-emitting diodes (LED) treatment promotes retinal healing and improve visual function following high intensity laser retinal injury by augmenting cellular energy metabolism, enhances mitochondrial function, increases cytochrome C oxidase activity, stimulates antioxidant protective pathways, and promotes cell survival. LED directly benefits injured neurons in the retina, the lateral geniculate nucleus, and the visual cortex, where perception occurs.

From a public health perspective, a Light-Emitting Diode (LED) Array study is important to conduct because it has been approved as a non-significant risk (NSR) device for treatment of eye disorders, it has a low cost of treatment, and it may serve as an effective, non-invasive alternative or adjunctive treatment to laser photocoagulation, the current standard of care for diabetic macular edema (DME). Study Objectives and Hypotheses To determine the effects of short term (3 month) near-infrared light (NIR) therapy on anatomic and functional abnormalities of diabetic macular edema as assessed by visual acuity, optical coherence tomography, multifocal electroretinography (mERG) and fundus bimicroscopy. To assess safety of short term near-infrared light therapy in eyes with diabetic macular edema. This therapeutic study may be reviewed at:

   
1 2 3 4 5
Home | About us | ERCS | Facilities | Queries | Links | Contact us